Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $124.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
TCHBF On Other Exchanges
SIX Swiss Ex
As of 4:30 PM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

tecan group ag-reg (TCHBF) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - $129.25
52 Week Low
10/3/14 - $108.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TECAN GROUP AG-REG (TCHBF)

Related News

No related news articles were found.

tecan group ag-reg (TCHBF) Related Businessweek News

No Related Businessweek News Found

tecan group ag-reg (TCHBF) Details

Tecan Group Ltd. provides laboratory instruments and automated workflow solutions for pharmaceutical and biotechnology companies, government research institutions and universities, diagnostic laboratories, and various applied markets. The company operates in two segments, Life Sciences Business and Partnering Business. It develops, produces, and distributes automation solutions, including instruments, software packages, numerous configurable modules, and special application knowhow, as well as consulting, services, and consumables. The company offers liquid handling platforms, which are used to pipette fluids with optimum precision and automate laborious and repetitive manual procedures; a range of bioanalytical instruments, such as microplate readers and washers that allows reactions to be monitored or analytes to be measured; and immunoassays for life science research and routine clinical diagnostics. It also develops and manufactures original equipment manufacturer instruments and components; and supplies laboratory instrument manufacturers with various components, such as precision pumps, valves, robotic arms, and development software under the Cavro brand. In addition, the company offers dedicated automation solutions comprising Dako Omnis, which is used in tissue-based cancer diagnostics; platform-based automation solutions; and pipette tips that acts as a component of a validated workflow solution, as well as detection instruments. Further, it provides ORTHO VISION analyzer, a diagnostics instrument that is used for blood typing; and determining other blood parameters. Tecan Group Ltd. distributes its products through its own market organization and distributors in approximately 50 countries worldwide. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

1,100 Employees
Last Reported Date: 03/27/15
Founded in 1980

tecan group ag-reg (TCHBF) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: SFr.855.0K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: SFr.459.0K
Compensation as of Fiscal Year 2014.

tecan group ag-reg (TCHBF) Key Developments

Tecan Group AG Reports Earnings Results for the First Half Ended June 30, 2015; Provides Earnings Outlook for the Year 2015

Tecan Group AG reported earnings results for the first half ended June 30, 2015. For the period, the company’s sales were climbed by 18.9% in local currencies or 16.2% in Swiss francs to CHF 200.0 million against CHF 172.0 million for same period a year ago. Excluding the IBL International business, which was consolidated on August 1, 2014, the company grew by 13.0% in local currencies or 10.5% in Swiss francs. Operating profit before depreciation and amortization (earnings before interest, taxes, depreciation and amortization; EBITDA) rose by 21.4% to CHF 32.6 million against CHF 26.8 million for same period a year ago. The company’s net profit increased by 39.7% to CHF 26.0 million against CHF 18.6 million for same period a year ago. Earnings per share were increased by 37.5% to CHF 2.31 against CHF 1.68 for same period a year ago. Cash flow from operating activities more than doubled to CHF 35.1 million against CHF 16.2 million for same period a year ago. For fiscal 2015, the company continues to anticipate Group sales growth in the double-digit percentage range in local currencies, with an increase in the EBITDA margin of more than 100 basis points. The expectations regarding profitability are based on an average exchange rate forecast for full-year 2015 of one euro equaling CHF 1.05 and one US dollar equaling CHF 0.92, and exclude further acquisitions.

Tecan Group Ltd., H1 2015 Earnings Call, Aug 12, 2015

Tecan Group Ltd., H1 2015 Earnings Call, Aug 12, 2015

Tecan Launches New Options for Spark 10M

Tecan has introduced a number of new features for the Spark 10M multimode reader. These first updates to the innovative Spark 10M include a cuvette port for absorbance measurements and an enhanced detection module, offering straightforward performance of immunoassays using PerkinElmer’s Alpha Technology, as well as a number of advanced software features. The enhanced detection module makes it easier than ever before for customers to perform AlphaScreen, AlphaLISA and AlphaPlex protocols. This option combines a high power laser light source with both low-pass and high-pass filters, using pre-optimized filter settings to ensure exceptional assay performance in 96- and 384 well microplate formats. The introduction of a cuvette port further increases format flexibility, allowing ultra-fast absorbance measurements using Tecan’s patent-pending High Speed Monochromators. The instrument’s SparkControl software has also been enhanced, with a number of new and improved features to streamline routine activities and maximize productivity. The extended dynamic range option enables both low and high gain measurements within a single microplate, allowing user to obtain complete data sets without compromising on sensitivity for low signal strength measurements. This is complemented by an automated gain regulation function for fluorescence-based measurements. Ideally suited to kinetic assays and long-term cell-based studies, this feature helps to avoid loss of data by automatically adjusting the gain settings if signal saturation is reached. The software then automatically correlates the data across different gain settings, allowing user to view the entire dataset in a single graph. In addition, the introduction of unique, one-click applications including absorbance reading, cell counting, cell viability, nucleic acid quantification and nucleic acid labelling efficiency makes it easy to perform optimized measurements, offering rapid, consistent results at the touch of a button.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TCHBF:US $124.00 USD 0.00

TCHBF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TCHBF.
View Industry Companies

Industry Analysis


Industry Average

Valuation TCHBF Industry Range
Price/Earnings 29.5x
Price/Sales 3.2x
Price/Book 3.6x
Price/Cash Flow 29.5x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TECAN GROUP AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at